Investors in Neurocrine Biosciences (NASDAQ:NBIX) Have Seen Notable Returns of 53% Over the Past Three Years
Investors in Neurocrine Biosciences (NASDAQ:NBIX) Have Seen Notable Returns of 53% Over the Past Three Years
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. For example, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shareholders have seen the share price rise 53% over three years, well in excess of the market return (20%, not including dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 5.8% in the last year.
从股市中获利的一个简单方法是买入指数基金。但如果您选择正确的个别股票,可能会获得更高回报。例如,神经分泌生物科学(NASDAQ:NBIX)的股东在三年内看到股价上涨了53%,远远超过市场回报(20%,不包括股息)。然而,最近的回报并不像那样令人印象深刻,该股票仅在过去一年内回报5.8%。
So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.
那么,让我们调查一下并查看公司的长期表现是否符合基本业务的进展。
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.
引用巴菲特的话说,“船只会在世界各地航行,但是持平地球学会会蓬勃发展。在市场上,价格和价值之间将继续存在巨大的差距……”评估公司周围情绪变化的一种有缺陷但合理的方法是将每股收益(EPS)与股价进行比较。
During the three years of share price growth, Neurocrine Biosciences actually saw its earnings per share (EPS) drop 6.9% per year.
在股价增长的三年期间,神经分泌生物科学实际上看到其每股收益(EPS)每年下降了6.9%。
Thus, it seems unlikely that the market is focussed on EPS growth at the moment. Therefore, we think it's worth considering other metrics as well.
因此,目前市场似乎不太关注每股收益增长。因此,我们认为考虑其他指标也是值得的。
It may well be that Neurocrine Biosciences revenue growth rate of 24% over three years has convinced shareholders to believe in a brighter future. In that case, the company may be sacrificing current earnings per share to drive growth, and maybe shareholder's faith in better days ahead will be rewarded.
神经分泌生物科学在过去三年实现了24%的营业收入增长率,这可能已经让股东相信公司的未来会更加光明。如果是这种情况,公司可能正在牺牲当前每股收益来推动增长,也许股东对未来更美好的信念将得到回报。
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. If you are thinking of buying or selling Neurocrine Biosciences stock, you should check out this free report showing analyst profit forecasts.
我们很高兴地报告,该CEO的报酬比同类市值公司的大多数CEO都要适中。关注CEO的薪酬是值得的,但更重要的问题是公司是否会在未来年份实现盈利增长。如果您在考虑买入或卖出神经分泌生物科学的股票,您应该查看这份展示分析师利润预测的免费报告。
A Different Perspective
另一种看法
Neurocrine Biosciences provided a TSR of 5.8% over the last twelve months. But that return falls short of the market. On the bright side, that's still a gain, and it's actually better than the average return of 2% over half a decade This suggests the company might be improving over time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Neurocrine Biosciences .
神经分泌生物科学在过去十二个月提供了5.8%的总股东回报率。但这一回报仍落后于市场水平。从积极方面来看,这仍然是一种收益,实际上比过去半个世纪的平均回报率2%更好。这表明该公司可能在不断改善。虽然考虑市场状况可能对股价产生的不同影响是非常值得的,但还有其他更重要的因素。因此,您应该注意到我们发现的神经分泌生物科学的2个警示信号。
We will like Neurocrine Biosciences better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
如果我们看到一些大规模内部人士买入神经分泌生物科学,我们会更喜欢它。在等待期间,请查看这份免费的低估股票名单(主要是小市值股票),其中包括相当多的最近内部人员买入情况。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。